What are the major weight management companies?

Four major weight management positions: (1) Hims & Hers Health (HIMS) — telehealth platform with compounded GLP-1 expansion; (2) WW International (WW) — multi-decade WeightWatchers facing structural decline; (3) Novo Nordisk (NVO ADR) — Ozempic/Wegovy GLP-1 franchise leadership; (4) Eli Lilly (LLY) — Mounjaro/Zepbound GLP-1 franchise with next-generation pipeline. The space has dramatic structural disruption.

How does GLP-1 therapy reshape weight management?

Multi-year GLP-1 receptor agonist therapy adoption (Ozempic, Wegovy, Mounjaro, Zepbound) dramatically reshapes weight management market. Therapies typically produce 15-25%+ body weight reduction over 12-24 months. Multi-year demand exceeds manufacturer capacity creating sustained shortages. Multi-billion-dollar revenue trajectory at Novo Nordisk plus Eli Lilly. The therapy disrupts traditional programs (WeightWatchers), supplement makers, plus broader weight management ecosystem.

How does Hims & Hers exploit telehealth disruption?

Hims & Hers Health operates telehealth platform expanded across multiple therapeutic categories including weight management. Multi-year compounded GLP-1 weight management revenue scaling drove substantial 2024-2025 revenue growth. Telehealth subscription model plus direct-to-consumer pharmacy fulfillment plus compounded semaglutide pricing below branded GLP-1 drove customer acquisition. Multi-year FDA regulatory dynamics affect compounding viability.

Why is WeightWatchers in structural decline?

WW International (WeightWatchers) faces multi-year structural decline as consumers shift to GLP-1 therapies. Multi-decade behavioral weight loss program model (meetings, points-based tracking) faces competitive pressure from medication-based approaches producing dramatically better outcomes. WW acquired Sequence (now WeightWatchers Clinic) for GLP-1 telehealth access but faces continued structural pressure. Reading subscriber trends drives institutional positioning.

What is the compounding pharmacy dynamic?

Compounding pharmacies plus telehealth operators provide compounded semaglutide (Novo Nordisk's active ingredient) alternatives during GLP-1 shortages. FDA shortage list status enables compounding for shortage drugs; removal from shortage list eliminates compounding authority. Multi-year FDA regulatory framework dynamics plus court proceedings (Outsourcing Facility Compounding Coalition litigation) affect compounding economics. Telehealth operators face shortage list changes.

What signals weight management cycle inflections?

Four signals: (1) GLP-1 capacity scaling plus shortage list status at Novo Nordisk and Eli Lilly; (2) FDA regulatory framework dynamics affecting compounding; (3) telehealth subscriber growth at Hims & Hers and competitors; (4) traditional program subscriber trends. Concentrated 13F changes around these signals reveal manager cycle reading.

Learn

Weight Management 13Fs: Hims, WeightWatchers, Novo Nordisk

Hims & Hers Health, WW International (formerly WeightWatchers), Novo Nordisk (NVO ADR), Eli Lilly (LLY), and Roche anchor US-traded weight management 13F positioning. GLP-1 therapy economics, telehealth disruption, traditional program decline, and compounding pharmacy dynamics drive distinctive institutional patterns.

By Sarah Mitchell, Education Editor

PublishedMay 16, 2026UpdatedMay 16, 2026

US-traded weight management equities form a distinctive healthcare-and-consumer-services corner of institutional 13F positioning facing dramatic structural disruption. Hims & Hers Health, WW International (WW, formerly WeightWatchers), Novo Nordisk (NVO ADR), and Eli Lilly anchor the cohort. Multi-year GLP-1 therapy economics (Ozempic, Wegovy, Mounjaro, Zepbound), telehealth disruption of traditional weight management, traditional program (WeightWatchers) structural decline, and compounding pharmacy dynamics drive distinctive institutional patterns. Reading weight management 13F positioning requires understanding the GLP-1 framework plus the multi-year telehealth and compounding cycle dynamics.

The weight management landscape

Weight management faces four primary economic drivers:

GLP-1 therapy economics. Multi-year GLP-1 receptor agonist therapy adoption (Novo Nordisk Ozempic/Wegovy, Eli Lilly Mounjaro/Zepbound) dramatically reshapes weight management market. Multi-year demand exceeds manufacturer capacity.
Telehealth disruption. Telehealth operators (Hims & Hers, Ro, Noom, Cerebral) disrupt traditional in-person weight management plus pharmacy distribution.
Traditional program structural decline. WeightWatchers plus other traditional programs face multi-year structural decline as consumers shift to GLP-1 therapies.
Compounding pharmacy dynamics. Compounding pharmacies plus telehealth operators provide compounded semaglutide alternatives during GLP-1 shortages. Multi-year FDA regulatory framework dynamics affect compounding economics.

Major US-traded weight management names

Hims & Hers Health (HIMS)

Telehealth platform expanded into compounded GLP-1 weight management plus hair loss plus sexual health plus mental health plus dermatology. Multi-year compounded GLP-1 revenue scaling.

WW International (WW)

Multi-decade WeightWatchers brand facing structural decline. Multi-year operational restructuring plus emerging GLP-1 telehealth program (acquired Sequence/WeightWatchers Clinic).

Novo Nordisk (NVO ADR)

Danish-headquartered global pharmaceutical with Ozempic (Type 2 diabetes) plus Wegovy (obesity) GLP-1 franchise leadership. Multi-year capacity scaling plus next-generation pipeline.

Eli Lilly (LLY)

US pharmaceutical with Mounjaro (Type 2 diabetes) plus Zepbound (obesity) GLP-1 franchise. Multi-year capacity expansion plus next-generation pipeline (retatrutide, orforglipron oral).

How institutional managers position around weight management

Three patterns:

Pattern 1: GLP-1 manufacturer concentration

NVO and LLY-concentrated growth manager positions reflect GLP-1 manufacturer leadership thesis.

Pattern 2: Telehealth disruption positioning

HIMS-concentrated active manager positions reflect telehealth disruption plus compounded GLP-1 thesis.

Pattern 3: Structural-decline avoidance

WW positions reflect structural decline avoidance — many active managers exit traditional programs as GLP-1 disrupts.

How to read weight management 13F positioning

Three rules:

Rule 1: Identify GLP-1 exposure

Each operator's GLP-1 exposure determines structural positioning.

Rule 2: Watch FDA shortage list

FDA GLP-1 shortage list status affects compounding economics.

Rule 3: Cross-check telehealth scaling

Multi-year telehealth scaling drives long-cycle thesis.

What weight management positioning signals

GLP-1 manufacturer conviction. Concentrated NVO and LLY positions signal manufacturer leadership thesis.
Telehealth disruption conviction. Concentrated HIMS positions signal telehealth disruption thesis.
Structural-decline avoidance. WW exclusion reflects manager structural decline avoidance.

For real-time tracking of weight management 13F activity, see the institutional signals feed.

Sarah MitchellEducation Editor

Investment Education Editor at 13F Insight. Breaks down complex institutional data into actionable insights for individual investors.